1. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated remains one of the most stable large-cap biotech names, supported by strong cash flow and pipeline expansion. On April 13, Bank of America reiterated the stock as a top pick for 2026 with a $598 price target.
The firm highlighted the company’s cystic fibrosis franchise as a major cash generator. Products such as Trikafta/Kaftrio and Alyftrek continue to drive consistent revenue, funding pipeline development.
Vertex recently received FDA approval to expand the use of ALYFTREK for patients aged six and older. The approval was supported by clinical and in vitro data covering hundreds of responsive genetic variants.
In parallel, the company is advancing its rare kidney disease pipeline. Encouraging results from povetacicept in IgA nephropathy position it as a potential long-term growth driver.
On March 19, Argus raised its price target to $520, citing continued strength in the cystic fibrosis portfolio and expanding treatment reach.
Vertex combines strong existing revenue with pipeline-driven growth, making it one of the most balanced biotech stocks in the market.
READ ALSO: Top 10 Biotech Stocks That Could Explode in 2026 and Top 10 Small-Cap FDA Catalyst Biotech Stocks.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
